Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velinotamig Monotherapy in Relapsed/Refractory Multiple Myeloma
NCT07102706Phase 2Completed
- Sponsor
- Zhixiang Jintai
- Start
- May 2022
- Primary completion
- May 2025
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of velinotamig in multiple myeloma (MM), sponsored by Zhixiang Jintai. Started May 2022; status: completed.
02
Drugs
velinotamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07102706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102706.